Drug Clinical Trial
Jump to navigation
Jump to search
A Drug Clinical Trial is a clinical trial for a drug therapeutic.
- Example(s):
- Trial: Elevate UC 12 (NCT03996369) [1]; Treatment type: Small molecule; Disease: Ulcerative colitis.
- Trial: VAT008 (NCT04904549) [2] ; Treatment type: Protein vaccine; Disease: COVID-19.
- Trial: Graduate 2 (NCT03444870) [3]; Treatment type: Antibody; Disease: Alzheimer's.
- Trial: NCT04853368 [4]; Treatment type: Small molecule; Disease: Cystic fibrosis.
- Trial: TROPiCS-02 (NCT03901339) [5]; Disease: Breast cancer; Treatment type: Antibody-drug conjugate.
- Trial: EMERGENT-2 (NCT04659161) [6]; Disease: Schizophrenia; Treatment type: Small molecule.
- Trial: ALPHA-2 (NCT04416984) [7]; Treatment type: Cell therapy; Disease: Large B-cell lymphoma.
- …
- Counter-Example(s):
- See: COVID-19 Vaccine Clinical Trial.
References
2022
- "10 clinical trials to watch in the first half of 2022."
- QUOTE: ... Positive clinical trial results — events that companies can use to sway investors, cut deals and raise cash — could help turn things around. And multiple opportunities lie ahead, with key studies in breast cancer, cystic fibrosis and ulcerative colitis set to read out in the first half of the year. ...
- Trial: Elevate UC 12 (NCT03996369)
Treatment type: Small molecule;
Disease: Ulcerative colitis. - Trial: VAT008 (NCT04904549);
Treatment type: Protein vaccine;
Disease: COVID-19. - Trial: Graduate 2 (NCT03444870);
Treatment type: Antibody;
Disease: Alzheimer's. - Trial: NCT04853368;
Treatment type: Small molecule;
Disease: Cystic fibrosis. - Trial: TROPiCS-02 (NCT03901339);
Disease: Breast cancer;
Treatment type: Antibody-drug conjugate. - Trial: EMERGENT-2 (NCT04659161);
Disease: Schizophrenia;
Treatment type: Small molecule. - Trial: ALPHA-2 (NCT04416984);
Treatment type: Cell therapy;
Disease: Large B-cell lymphoma. - …
- Trial: Elevate UC 12 (NCT03996369)
- QUOTE: ... Positive clinical trial results — events that companies can use to sway investors, cut deals and raise cash — could help turn things around. And multiple opportunities lie ahead, with key studies in breast cancer, cystic fibrosis and ulcerative colitis set to read out in the first half of the year. ...